From Wikipedia, the free encyclopedia
Medication to treat hair loss
Ritlecitinib
Trade names Litfulo Other names PF-06651600
License data
Routes of administration
By mouth
ATC code
Legal status
1-[(2S ,5R )-2-methyl-5-(7H -pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
CAS Number
PubChem
CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Formula C 15 H 19 N 5 O
Molar mass 285.351 g·mol−1 3D model (
JSmol )
C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=C3C=CNC3=NC=N2
InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
Key:CBRJPFGIXUFMTM-WDEREUQCSA-N
Key:YOZLVAFWYLSRRN-VZXYPILPSA-N
Ritlecitinib , sold under the brand name Litfulo , is a medication used for the treatment of severe
alopecia areata (
hair loss ).
[4] Ritlecitinib is a
kinase inhibitor which inhibits
Janus kinase 3 and
tyrosine kinase .
[4]
[7]
[8]
Ritlecitinib was approved for medical use in the United States in June 2023,
[4]
[9] in the European Union in September 2023,
[5] and in Canada in February 2024.
[2]
Medical uses
Ritlecitinib is
indicated for the treatment of severe
alopecia areata for individuals aged 12 and over.
[4]
[5]
Society and culture
Economics
The annual list price of a prescription is $49,000.
[10]
References
Further reading
Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, et al. (April 2022).
"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers" . The Journal of Allergy and Clinical Immunology . 149 (4): 1318–1328.
doi :
10.1016/j.jaci.2021.10.036 .
PMID
34863853 .
S2CID
244824663 .
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. (May 2023). "Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial". Lancet . 401 (10387). London, England: 1518–1529.
doi :
10.1016/S0140-6736(23)00222-2 .
PMID
37062298 .
S2CID
258114404 .
External links
Chemokine
CSF
Interferon
IFNAR (α/β, I)
Agonists:
Albinterferon
Interferon alpha (interferon alfa, IFN-α)
Interferon alfa (
IFNA1 ,
IFNA2 ,
IFNA4 ,
IFNA5 ,
IFNA6 ,
IFNA7 ,
IFNA8 ,
IFNA10 ,
IFNA13 ,
IFNA14 ,
IFNA16 ,
IFNA17 ,
IFNA21 )
Interferon alfa 2a
Interferon alfa 2b
Interferon alfa n1
Interferon alfacon-1
Interferon alpha-n3
Interferon beta (IFN-β) (
IFNB1 ,
IFNB3 )
Interferon beta 1a
Interferon beta 1b
Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
Interferon omega (IFN-ω, IFNW1)
Peginterferon alfa-2a
Peginterferon alfa-2b
IFNGR (γ, II)
IFNLR (λ, III)
See IL-28R (IFNLR)
here instead.
Interleukin
TGFβ
TNF Others